Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (clozaril, denzapine, and zaponex)

Therapeutic Drug Monitoring

Volumn 32, Issue 5, 2010, Pages 624-627

  Couchman, Lewis ^a   Morgan, Phillip Edgar ^a   Spencer, Edgar Pathrose ^b   Johnston, Atholl ^c   Flanagan, Robert James ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

bioequivalence; clozapine brands; clozapine TDM; switching brands

Indexed keywords

CLOZAPINE; DENZAPINE; NORCLOZAPINE; UNCLASSIFIED DRUG; ZAPONEX;

ADOLESCENT; ADULT; ARTICLE; BIOEQUIVALENCE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LIQUID; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; STATISTICAL ANALYSIS; TABLET FORMULATION; UNITED KINGDOM;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; SMOKING; THERAPEUTIC EQUIVALENCY;

EID: 77957265421     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181f0a1a2     Document Type: Article

References (18)

1. National Institute for Health and Clinical Excellence (NICE). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (update). NICE, 2009. Available at: http://www.nice.org.uk/nicemedia/pdf/CG82FullGuideline.pdf. Accessed December 11, 2009.
2. Pokorny R, Finkel MJ, Robinson WT. Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine. Pharm Res. 1994;11:1221.
3. Food and Drug Administration and Center for Drug Evaluation and Research (FDA/CDER). Guidance for Industry. Clozapine: In Vivo Bioequivalence and In Vitro Dissolution Testing. FDA/CDER, 2005. Available at: http://www.fda.gov/ downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm070232. pdf. Accessed November 16, 2009.
4. Lam YW, Ereshefsky L, Toney GB, et al. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry. 2001;62(Suppl 5):18-22. (Pubitemid 32295160)
5. Mofsen R, Balter J. Case reports of the re-emergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther. 2001;23:1720-1731.
6. Kluznik JC, Walbek NH, Farnsworth MG, et al. Clinical effects of a randomised switch of patients from clozaril to generic clozapine. J Clin Psychiatry. 2001;62(Suppl 5):14-17.
7. Makela EH, Cutlip WD, Stevenson JM, et al. Branded versus generic clozapine for treatment of schizophrenia. Ann Pharmacother. 2003;37: 350-353.
8. Tse G, Thompson D, Procyshyn R. Generic clozapine: a cost-saving alternative to brand name clozapine? Pharmacoeconomics. 2003;21: 1-11.
9. Paton C. Generic clozapine: outcomes after switching formulations. Br J Psychiatry. 2006;189:184-185.
10. Perry PJ, Miller D, Arndt SV, et al. Clozapine and norclozapine concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148:231-235.
11. Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol. 2004;24:70-78.
12. McCarthy PT, Hughes S, Paton C. Measurement of clozapine and norclozapine in plasma and serum by high-performance liquid-chromatography with ultraviolet detection. Biomed Chromatogr. 1995;9:36-41.
13. European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on the Investigation of Bioavailability and Bioequivalence. EMEA, 2001. Available at: http://www.emea.europa.eu/pdfs/human/qwp/140198enfin.pdf. Accessed December 15, 2009.
14. Food and Drug Administration and Center for Drug Evaluation and Research (FDA/CDER). Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. FDA/CDER, 2002. Available at: http://www.fda. gov/downloads/Drugs/DevelopmentApprovalProcess/ HowDrugsAre DevelopedandApproved/ApprovalApplications/AbbreviatedNewDrug ApplicationANDAGenerics/UCM154838.pdf. Accessed November 16, 2009.
15. Borgherini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003;25: 1578-1592.
16. Nuss P, Taylor D, De Hert M, et al. The generic alternative in schizophrenia: opportunity or threat? CNS Drugs. 2004;18:769-775.
17. Flanagan RJ. Side-effects of clozapine and some other psychoactive drugs. Current Drug Saf. 2008;3:115-122.
18. Taylor D, Paton C, Kapur S. Prescribing Guidelines. Edition 10. London: Informa Healthcare; 2009.